Burns, Madeleine D.
Bartsch, Yannic C.
Davis, Jameson P.
Boribong, Brittany P.
Loiselle, Maggie
Kang, Jaewon
Kane, Abigail S.
Edlow, Andrea G.
Fasano, Alessio
Alter, Galit
Yonker, Lael M.
Article History
Received: 11 November 2022
Revised: 21 March 2023
Accepted: 30 March 2023
First Online: 12 May 2023
Competing interests
: G.A. is a V.P. at Moderna, a founder and equity holder of Seromyx Systems, and an employee and equity holder of Leyden Labs. G.A.’s interests were reviewed and are managed by MGH and Partners HealthCare in accordance with their conflict-of-interest policies. A.G.E. reported serving as a medical advisor for Mirvie, Inc. and receiving research funding from Merck & Co. outside of the scope of the submitted work. No other disclosures were reported. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
: Informed consent, and where appropriate, assent, was verbally obtained from participants and/or parents/guardians involved in the study. The study was approved by the Institutional Review Board of Massachusetts General Brigham (IRB #2020P000955, approved 12/14/20).
Free to read: This content has been made available to all.